Body weight homeostat that regulates fat mass independently of leptin in rats and mice

John-Olov Jansson\textsuperscript{a,1}, Vilborg Palsdottir\textsuperscript{a}, Daniel A. Hägg\textsuperscript{b}, Erik Schéle\textsuperscript{a}, Suzanne L. Dickson\textsuperscript{c}, Fredrik Anesten\textsuperscript{a}, Tina Bake\textsuperscript{d}, Mikael Montelius\textsuperscript{e}, Jakob Bellman\textsuperscript{f}, Maria E. Johansson\textsuperscript{g}, Roger D. Cone\textsuperscript{a,9}, Daniel J. Drucker\textsuperscript{h}, Jianyao Wu\textsuperscript{i}, Biljana Aleksic\textsuperscript{j}, Anna E. Törnqvist\textsuperscript{k}, Klara Sjögren\textsuperscript{l}, Jan-Åke Gustafsson\textsuperscript{g,1}, Sara H. Windahl\textsuperscript{p}, and Claes Ohlsson\textsuperscript{b,1}

\textsuperscript{a}Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, SE 405 30, Gothenburg, Sweden; \textsuperscript{b}Centre for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, SE 413 45, Gothenburg, Sweden; \textsuperscript{c}Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, SE 413 45, Gothenburg, Sweden; \textsuperscript{d}Life Sciences Institute, University of Michigan, Ann Arbor, MI 48109-2216; \textsuperscript{e}Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI 48109-2216; \textsuperscript{f}Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, ON M5G 1X5, Toronto, Canada; and \textsuperscript{g}Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, TX 77204

Contributed by Jan-Åke Gustafsson, November 8, 2017 (sent for review September 7, 2017; reviewed by Wolfgang Langhans and Subburaman Mohan)

Subjects spending much time sitting have increased risk of obesity but the mechanism for the antiobesity effect of standing is unknown. We hypothesized that there is a homeostatic regulation of body weight. We demonstrate that increased loading of rodents, achieved using capsules with different weights implanted in the abdomen or s.c. on the back, reversibly decreases the biological body weight via reduced food intake. Importantly, loading relieves diet-induced obesity and improves glucose tolerance. The identified homeostat for body weight regulates body fat mass independently of fat-derived leptin, revealing two independent negative feedback systems for fat mass regulation. It is known that osteocytes can sense changes in bone strain. In this study, the body weight-reducing effect of increased loading was lost in mice depleted of osteocytes. We propose that increased body weight activates a sensor dependent on osteocytes of the weight-bearing bones. This induces anafferent signal, which reduces body weight. These findings demonstrate a leptin-independent body weight homeostat (“gravitostat”) that regulates fat mass.

| diet-induced obesity | weight loss | osteocytes | glucose metabolism |

Epidemiologic studies demonstrate that subjects spending much time sitting have increased risk of obesity, diabetes, and cardiovascular diseases. There is even epidemiologic evidence for an association between sitting time and overall mortality (1, 2). The mechanism for the antiobesity effect of standing is essentially unknown. It is probable that part of the effect of high sitting time on cardiometabolic phenotypes is caused by the associated low degree of exercise. However, the results of some articles demonstrate that the association of a sedentary behavior, as reflected by much sitting time, with the metabolic syndrome, is independent of physical activity (3, 4). We hypothesized that there is a homeostat (5) in the lower extremities regulating body weight with an impact on fat mass. Such a homeostat would (together with leptin) ensure sufficient whole body energy depots but still protect land-living animals from becoming too heavy. A prerequisite for such a homeostatic regulation of body weight is that the integration center, which may be in the brain, receives afferent information from a body weight sensor. Thereafter, the integration center may adjust the body weight by acting on an effector (6).

Results

Body Weight Sensing for Fat Mass Homeostasis in Mice with Diet-Induced Obesity. To investigate our hypothesis that there is a homeostatic regulation of body weight and fat mass based on loading, we implanted capsules that weighed 15% of the body weight into the abdomen of adult Sprague-Dawley rats and C57BL6 mice with diet-induced obesity (load). Control animals were implanted with an empty capsule of equal size (3% of the body weight). We found that increased loading suppressed the biological body weight both in rats and mice (Fig. 1 A and B). The difference in biological body weight between rodents with load and control rodents was first seen on day 2 after implantation and was larger on day 14 when the experiment was terminated (Fig. 1 A and B). At the end of the experiment the total body weight (= biological body weight + capsule weight) was similar in the load and control mice (Fig. S1A). Calculations of the efficiency of the homeostatic regulation of total body weight at 2 wk after initiation of the loading revealed that ~80% of the increased loading was counteracted by reduced biological weight (Fig. S1B). The increased loading also reduced the amount of white adipose tissue (WAT), as illustrated by representative MRI slices (Fig. 1C) and quantified by WAT dissection (Fig. 1D) and serum leptin levels (Fig. 1E). These findings demonstrate that there is an efficient body weight sensing mechanism for the homeostatic regulation of body weight. The possible mechanism behind the suppression of body weight by increased loading was investigated on day 6 after implantation of capsules, a time point when the difference in body weight was still robustly increasing between load and control rodents (Fig. 1A and B). There was no significant difference between mice with load and control mice in UCP1 mRNA levels in brown adipose tissue (BAT) (Fig. S1C), in oxygen consumption as a measure of energy expenditure (Fig. S1D), in respiratory quotient (RQ) (Fig. S1E), or in motor activity (Fig. S1F). Importantly, load decreased food intake, both calculated as percent of body weight (Fig. 1 F

Significance

The only known homeostatic regulator of fat mass is the leptin system. We hypothesized that there is a second homeostat regulating body weight with an impact on fat mass. In this study we have added and removed weight loads from experimental animals and measured the effects on the biological body weight. The results demonstrate that there is a body weight homeostat that regulates fat mass independently of leptin. As the body weight-reducing effect of increased loading was dependent on osteocytes, we propose that there is a sensor for body weight in the long bones of the lower extremities acting as “body scales.” This is part of a body weight homeostat, “gravitostat,” that keeps body weight and body fat mass constant.


Reviews: W.L., ETH Zurich; and S.M., Jerry L. Pettis Memorial VA Medical Center and Loma Linda University.

The authors declare no conflict of interest.

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

Significance

The only known homeostatic regulator of fat mass is the leptin system. We hypothesized that there is a second homeostat regulating body weight with an impact on fat mass. In this study we have added and removed weight loads from experimental animals and measured the effects on the biological body weight. The results demonstrate that there is a body weight homeostat that regulates fat mass independently of leptin. As the body weight-reducing effect of increased loading was dependent on osteocytes, we propose that there is a sensor for body weight in the long bones of the lower extremities acting as “body scales.” This is part of a body weight homeostat, “gravitostat,” that keeps body weight and body fat mass constant.

www.pnas.org/cgi/doi/10.1073/pnas.1715687114

PNAS | January 9, 2018 | vol. 115 | no. 2 | 427–432
and G) and calculated as food intake per animal in both rats and mice (Fig. S1 G and H).

Control mice pair fed with the same amount of food as the load mice decreased their body weight to the same extent as the load group (Fig. 1H). Therefore, the decreased biological body weight in the animals with increased loading did not seem to be caused primarily by increased energy expenditure, but rather by decreased food intake. An alternative loading procedure using capsules implanted s.c. on the back of the mice was also used. Increased loading suppressed the biological body weight in adult mice with diet-induced obesity also in this model (Fig. S1I). These experiments revealed that increased loading reduces the biological body weight.

Fig. 1. Body weight sensing for fat mass homeostasis in rats and mice with diet-induced obesity. (A) Effect of loading on change in biological body weight (= total body weight - capsule weight) in rats (n = 8) and (B) mice (n = 10) implanted with capsules weighing 15% of the body weight (load) or empty capsules (control; ~1.5% and ~3% of the body weight for rats and mice, respectively). (C) Coronal (Top) and corresponding transversal (Bottom) MR images of a control (Left) and a load (Right) animal (day 14), acquired without fat suppression. Hyperintense regions represent body fat. Yellow dotted line and white bar indicate the position of the corresponding transversal images below and 10 mm, respectively. (D) The fat mass (day 14), (E) the serum leptin levels (day 14), and (F) the food intake as percent of body weight (days 4–6) were measured in load and control rats (n = 8) and (G) mice (n = 10). (H) The effect of pair feeding on body weight change in control mice compared with ad libitum fed control and load mice (n = 9). (I) Change in biological body weight, (J) the fat mass (day 17), and (K) the skeletal muscle mass (day 17) after removal of load (heavy capsule followed by empty capsule) or sustained load (heavy capsule followed by heavy capsule) 14 d after the first implantation (n = 10). (L) HOMA-IR in fasted control and load mice (n = 10). (M) Blood glucose, (N) blood glucose area under the curve (AUC), (O) serum insulin, and (P) insulin AUC during an oral glucose tolerance test in load and control mice (n = 10). (Q) Effect of loading on long-term change in biological body weight in load and control mice (n = 10) followed during 7 wk after capsule implantation. Data are expressed as mean ± SEM *P < 0.05, **P < 0.01, ***P < 0.001.
We next evaluated whether reduced loading also influences the biological body weight by comparing mice with sustained loading (heavy capsule followed by heavy capsule) and mice with removal of loading (heavy capsule followed by empty capsule; Fig. 1J). Removal of the loading increased the biological body weight and the fat mass (Fig. 1J) but not the skeletal muscle mass (Fig. 1K), demonstrating that the body weight sensor is functional in both directions.

Loading improved insulin sensitivity as indicated by substantially reduced fasting homeostatic model assessment of insulin resistance (HOMA-IR) index (Fig. 1L) and reduced serum insulin before, during, and after oral glucose administration compared with control mice (Fig. 1O and P). In addition, loading increased glucose tolerance as indicated by decreased levels of circulating glucose after oral glucose administration (Fig. 1M and N and Fig. S1K and L). Although loading reduced the absolute serum insulin levels throughout the glucose tolerance test (GTT) (Fig. 1O and P), the induction of serum insulin from baseline was normal during the test (Fig. S1M and N).

We also performed a long-term study, demonstrating that the effect of loading on biological body weight remained until the experiment was terminated at day 49 (Fig. 1Q).

Leptin-Independent Body Weight Sensing for Fat Mass Homeostasis.
A prerequisite for homeostatic feedback regulation of energy depositories in body fat tissue (energy balance) is that energy regulating parts of the brain receive information from fat tissue about its size. The fat-derived hormone leptin, discovered by Friedman and coworkers over 20 y ago, is so far the only known such afferent homeostatic factor (7–9). In the present study, we next investigated the interactions between increased loading, a stimulus normally reflecting increased body fat mass, and leptin. The loading-induced decrease in body weight was seen in leptin-deficient obese (Ob/Ob) mice (Fig. 2A), in the same way as in wild-type mice (Fig. 1D). In addition, the combined effect of increased loading and leptin treatment was studied in wild-type mice. Leptin was given to loaded and control mice on days 11–15 after implantation of capsules. It was found that leptin treatment suppressed body weight (Fig. 2B) and body fat (Fig. 2C) to a similar extent in loaded and control mice, while none of the treatments affected muscle mass (Fig. 2D). Thus, the loading-induced homeostatic regulation of body weight was independent of the well-established fat mass reducing effect of leptin, revealing two independent negative feedback systems for fat mass homeostasis.

Since the body weight reducing effect of increased loading was caused by reduced food intake, we analyzed the expression of appetite regulating genes in the hypothalamus. Increased loading augmented the expression of the obesity promoting neuropeptides AgRP and NPY (Fig. S1J). These two peptides are expressed by essentially the same neurons in the arcuate nucleus of the hypothalamus and their expression is suppressed by leptin. Therefore, the increase in AgRP and NPY expression is likely to be a failed compensatory mechanism induced by low fat mass and low serum leptin in the mice exposed to increased loading (Fig. 1D and E and Fig. S1J), consistent with a leptin-independent mechanism for increased loading to reduce body weight.

The Suppression of Body Weight and Fat Mass by Loading Is Dependent on Osteocytes. It is known that osteocytes can sense dynamic short-term high-impact bone loading for local bone adaptation (10–12). We therefore postulated that chronic static moderately increased bone loading, induced by increased body weight, also activates osteocytes, and thereby reduces fat mass via a systemic signal. To determine the role of osteocytes for the suppression of body weight by increased loading, we established an osteocyte-depleted transgenic mouse model using diphtheria toxin-driven cell depletion specifically of DMP1 positive osteocytes (Fig. S2). The normal suppression of body weight by increased loading observed in mice with intact osteocytes (Fig. 3A) was lost in osteocyte-depleted mice (Fig. 3B). Increased loading decreased the weight of WAT (Fig. 3C) and serum leptin levels (Fig. 3D) in mice with intact osteocytes but not in osteocyte-depleted mice, while there was no significant differences in the skeletal muscle weight between the groups (Fig. 3E). These findings demonstrate that the suppression of body weight by loading is dependent on osteocytes. We propose that increased body weight activates a sensor dependent on the osteocytes of the weight-bearing bones. This induces an afferent signal to reduce food intake (Fig. 3F).

A growing body of data indicates that the skeleton is an endocrine organ that regulates energy and glucose metabolism through, at least in part, the release of the bone-derived hormone osteocalcin (13, 14). We therefore hypothesized that the homeostatic regulation of body weight and fat mass by osteocytes in response to changes in
body weight may be mediated by osteocalcin, or another known bone-derived circulating factor. To investigate this hypothesis, we determined the effect of increased loading for 6 d on the bone expression and circulating levels of four bone-derived candidate factors (sclerostin, osteocalcin, FGF23, and lipocalin 2) that might mediate this effect (Fig. S3). As previously shown for dynamic short-term high-impact loading, static moderately increased loading for 6 d reduced the bone expression of Sox (the gene coding for the bone mass suppressing factor sclerostin) (Fig. S3A). However, serum levels of sclerostin were not affected by increased loading (Fig. S3B).

Although osteocalcin is a crucial regulator of energy metabolism in rodents, no effect of increased loading on the expression of osteocalcin in bone (Fig. S3C) or on circulating levels of total (Fig. S3D), carboxylated (Fig. S3E), or undercarboxylated (Fig. S3F) osteocalcin was observed. Furthermore, serum testosterone levels, known to be regulated by bone-derived osteocalcin and to regulate fat mass, were not affected by loading (15) (Fig. S3G). FGF23 is an osteocyte-derived endocrine acting factor. Increased loading did not significantly alter FGF23 expression in bone (Fig. S3H) or serum FGF23 levels (Fig. S3I). It was recently demonstrated that bone-derived lipocalin 2 suppresses appetite via a MC4R-dependent pathway (16). Increased loading did not significantly alter lipocalin 2 mRNA levels in bone (Fig. S3J) or serum lipocalin 2 levels in mice (Fig. S3K). These findings do not support that any of the four main bone-derived circulating candidate factors mediate the effect of the osteocyte-dependent body weight sensing mechanism.

**Effect of Loading on Biological Body Weight in Relation to Other Known Body Fat Regulators.** As described above (Fig. 2A–B), the decrease in body weight by loading was independent of leptin. We next investigated the suppression of body weight by increased loading in relation to other known fat mass regulating signals (Fig. S4).

To regulate fat mass, the hypothalamus needs afferent signals from the gastrointestinal tract, e.g., by the hunger and adiposity-inducing hormone ghrelin (17). We found that loading suppressed body weight in mice lacking the ghrelin receptor (Fig. S4A). Moreover, body weight was decreased by loading in mice lacking the receptor for glucagon-like peptide 1 (GLP-1) (Fig. S4B), an insulin-releasing hormone, described to regulate body weight (18). Thus, we found no evidence that loading is dependent on fat mass-regulating signals from the gastrointestinal tract. A major regulator of body fat in the hypothalamus is the circuit involving the neuropeptide α-MSH acting on the melanocortin receptor-4 (MC4R) (19, 20). The body weight decreasing effect of loading was also found in MC4R gene knockout mice (Fig. S4C). Therefore, the suppression of body weight by loading is independent of the α-MSH MC4R system, a major mediator of effects by leptin and GLP-1. Estrogen receptor-α (ER-α) signaling is involved in the regulation of both fat mass and bone mass. It has been shown that local bone formation induced by short-term high-impact loading is dependent on ER-α (10). However, our results from ER-α knockout mice indicate that ER-α is dispensable for the systemic regulation of body weight induced by chronic static moderately increased loading (Fig. S4D). We next determined whether neuronal signaling might mediate the loading-induced decrease in body weight. However, neither the sympathetic marker...
noradrenaline in urine (Fig. S5A) nor the parasympathetic marker serum choline levels (Fig. S5B) were regulated by loading. These findings demonstrate that increased body weight activates a sensor dependent on the osteocytes of the weight-bearing bones. This induces an afferent food intake reducing signal that needs further study (Fig. 3F).

**Discussion**

The present findings reveal a body weight homeostat that regulates fat mass independently of leptin in rodents with diet-induced obesity. Increased body weight activates a sensor dependent on the osteocytes of the weight-bearing bones. This induces an afferent signal to reduce body weight.

We observed that increased loading decreased body weight, while decreased loading increases body weight, demonstrating that the body weight sensor is functional in both directions. Importantly, several authors have found that removal of fat by lipectomy causes a compensatory increase in fat mass and body weight in mice and rats lacking leptin activity (21–23). These data support our conclusion that a leptin-independent regulation of fat mass does exist, but they do not provide information about the possible mechanism. The present data, indicating that loading can regulate fat mass, raise the possibility that the increase in fat mass observed after lipectomy in leptin-deficient mice is due to decreased loading.

Increased loading reduced the biological body weight via reduced food intake. The normal motor activity and the notion that the effects of increased loading on food intake and body weight were specific.

It is well established that leptin signaling is necessary to prevent severe obesity (7, 24). However, most patients with obesity have high endogenous serum leptin levels and do not respond to exogenous leptin treatment. This indicates that, during these circumstances, leptin is not sufficient to suppress fat mass. This has been referred to as leptin resistance (7, 25).

We propose that both loading signaling and body weight sensing are necessary for an optimal fat mass homeostasis. Pharmacological or combined targeting of both the body weight sensing mechanism and leptin signaling may be useful for obesity treatment (Fig. 3F). In line with this, weight loading and leptin treatment suppressed body weight in an additive manner in the present study.

As described above, there is an established epidemiologic link between numbers of hours per day spent in the sitting position and several metabolic diseases, including obesity, diabetes, and cardiovascular diseases. However, the reason for this has been unknown (1, 2). We propose that much sitting time results in decreased body weight sensing mechanism, might have contributed to the obesity epidemic. The fact that loading was effective in decreasing fat mass in both Sprague-Dawley rats and C57BL/6 mice with diet-induced obesity, well established models of clinical obesity (26, 27), suggests that increased standing time and, thereby, increased loading will be effective in decreasing human obesity. In addition, our findings demonstrate that loading increases insulin sensitivity. Further studies are needed to investigate whether this effect is completely or only partly due to decreased body fat mass.

The present findings reveal a body weight homeostat that regulates fat mass independently of leptin. We suggest that this body weight homeostat is called “gravitostat” (Latin gravis, meaning heavy; Latin status, meaning stable). The gravitostat, like other homeostats is based on communication between a sensor, an integration center, and an effector. Its sensor is most likely located in the weight-bearing lower extremities. Our data indicate that at least part of this sensor is in osteocytes. Increased fat mass is counteracted both by the gravitostat and by increased fat-derived leptin (7, 24) (Fig. 3F). The gravitostat activates an afferent signal for body weight homeostasis to reduce food intake (Fig. 3F). Leptin has the capacity to decrease body weight, to some extent mediated by reduced food intake (7, 9). Therefore, both the gravitostat and leptin are eventually acting on the brain and seem to have their integrative centers there (Fig. 3F). Although both leptin and the gravitostat have the capacity to regulate fat mass, it has been proposed that the role of leptin primarily is in the lower end of fat mass homeostasis (25, 28), while the present data demonstrate that the gravitostat is efficient in diet-induced obesity. Future studies are warranted to determine whether activation of the gravitostat explains the beneficial effects of standing. Furthermore, when evaluated in a relevant disease model, it was observed that loading relieved diet-induced obesity and improved insulin sensitivity, suggesting the gravitostat is an interesting drug target for metabolic diseases (Fig. 3F).

**Materials and Methods**

**Animals.** All animal procedures were approved by the Ethics Committee on Animal Care and Use of Gothenburg University. C57BL/6 mice were purchased from Taconic, leptin-deficient Ob/Ob mice were obtained from The Jackson Laboratory and Ghrelin receptor knockout (GHSR KO) mice were obtained from Deltagen. MC4R KO mice, GLP-1R KO mice, and ErbB2 KO mice were developed as previously described (19, 20, 29, 30). All knockout mice and their controls were on a C57BL/6 background. Sprague-Dawley rats were purchased from Charles River Laboratories.

To generate the osteocyte-depleted mice, DMP-1 promoter-Cre mice (31) were crossed with ROSA26 promoter-Flox-STOP-Flox-DTR mice (32) (Fig. S2). Diptheria toxin receptor (DTR) mRNA was compared between cortical bone, kidney, and liver with RT-PCR (Fig. S2C). Sost mRNA was measured in cortical bone as a marker of osteocyte depletion (OCyD) in mice expressing DTR and given diptheria toxin (Fig. S2D).

**Immunohistochemistry.** The number of osteocytes and empty osteocyte lacunae in femur was evaluated blinded using a bright field microscope. Briefly, femur was fixed, paraffin embedded, sectioned, and stained with hematoxylin and eosin. Three evenly spread out sections of femur were used for counting. Osteocytes and empty lacunae were counted from cortical bone covering on average 0.16 mm² per section and located 5 mm from the tip of the epiphysial plate. The number of apoptotic osteocytes was measured as cells with TUNEL positive staining. Briefly, the femur sections neighboring the sections used for counting empty lacunae were stained using TUNEL assay (AppTag Fluoro-Rescin In Situ Apoptosis Detection Kit, S7110; Millipore) in accordance with instructions provided and counterstained with DAPI. Using a wide field fluorescent microscope (Leica DMRB; Leica Microsystems), images were taken covering on average 0.16 mm² of cortical bone per section and located 5 mm from the tip of the epiphysial plate. Background autofluorescence was reduced by applying a digital channel subtraction method to the images. TUNEL positive cells and DAPI positive cells were counted within the images.

In a separate experiment, blue β-gal staining of femoral bone sections was used as a marker of cells with active DMP-1 promoter. DMP-1 promoter-Cre mice or wild-type mice were crossed with ROSA26 promoter-Flox-STOP-Flox-β-gal mice. The staining with β-gal in cortical bone was compared between ROSA26 promoter-Flox-STOP-Flox-β-gal mice and without DMP-1 promoter-Cre.

**Loading.** Two- to 3-mo-old mice and rats were fed a high-fat diet (60% fat, D12492; Research Diets) during 4 wk and then a capsule that weighed 15% of the body weight (load) or 3% of the body weight (control) was implanted intraperitoneally or s.c. into the adult animals under isoflurane anesthesia. After the implantation, the body weight was measured daily or several times per week until the end of each experiment.

Removal of load was done in one experiment in which the capsules were exchanged 2 wk after the first surgery and half of the mice with load capsules got control capsules (removal of load) and half of them got new load capsules (sustained load) with a follow-up period of 3 wk after removal of load.

**Indirect Calorimetry, Food Intake, and Activity Measurement.** Oxygen consumption and carbon dioxide production was measured by indirect calorimetry in an INCA Metabolic System (Somedic) as previously described (33). The energy expenditure was calculated by the formula, energy expenditure (EE) = VO₂ + VCO₂. EE was measured in rats and mice loaded 2 wk after implantation of capsules in C57BL/6 mice and the food intake was monitored during the same period for both mice and rats. We also performed a pair feeding study, in which we fed control mice the same amount of food as ad libitum fed load mice. The motor activity was measured in automated activity chambers, so-called Locoboxes, consisting of a plastic cage (55 × 55 × 22 cm) inside a ventilated cabinet (Kungsbacka Mat-och Reglerteknik AB).

**Glucose Tolerance Test.** Oral GTT was performed on C57BL/6 mice 3 wk after capsule implantation. The mice received oral glucose [2 g/kg body weight (BW); Fresenius Kabi] by gavage after 5 h of fasting. Blood samples were collected from...
the tail vein at 0, 15, 30, 60, and 120 min after the glucose gavage. Blood glucose concentrations were determined at the above-mentioned time points using an Accu-Check system (Roche Diagnostics). Serum insulin concentrations were measured at time points 0, 15, 60, and 120 min after the glucose administration using the Ultrasensitive Mouse Insulin ELISA kit (90080, Crystal Chem, Inc.) according to the protocol provided by the manufacturer.

**Leptin Treatment.** Control and loaded C57BL/6 mice were given murine leptin (1.5 μg/g BW; Pepro-Tech) or saline twice daily in s.c. injections on days 11–15 after the capsule implantation.

**Gene Expression.** Cortical bone from femur and tibia, hypothalamus, and interscapular BAT were dissected, snap frozen in liquid nitrogen, and kept in –80 °C until analysis. The cortical bones were homogenized with Trizol reagent (Invitrogen) before extraction. mRNA from all tissues was extracted using RNeasy Lipid Tissue Mini Kit (Qiagen) and the mRNA concentration of the samples was measured by NanoDrop spectrophotometry. cDNA was synthesized from 1 μg mRNA with iScript cDNA Synthesis Kit (Bio-Rad).

Real-time PCR was performed using Step-One-Plus or the ABI Prism 7900 Sequence Detection System (Applied Biosystems). The hypothalamus samples were analyzed with Universal Taqman Master Mix (Applied Biosystems) in a 48-gene custom-made TaqMan low-density array card and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Mm99999915_g1). The cortical bone samples were analyzed by assays for osteocalcin (Mm01741771_g1), sclerostin (Mm00470479_m1), FF23 (Mm00456251_s1), and Icaritin 2 (Mm 01324470_m1) and normalized to 18S (Mm00465190_m1). The BAT samples were analyzed with an assay for Ucp1 (Mm01248466_m1) and normalized to 18S (Mm00271390_m1). The relative mRNA levels were obtained by using the comparative threshold cycle (Ct) method and calculated with the ΔΔCt equation.

**Serum and Urine Analyses.** Blood samples were collected at the end of each experiment and the serum was separated and kept in –80 °C until analysis. Serum was analyzed in duplicates by ELISAs for leptin (Crystal Chem, Inc), sclerostin (ALPCO immunoassays), osteocalcin (ImmunoLogic), Gla-osteocalcin (Takara Clontech), FF23 (Kainos Laboratories, Inc), Icaritin 2 (R&D Systems), and choline (Abcam). Serum testosterone was analyzed by a gas chromatography-tandem mass spectrometry method as previously described (34). Urine samples were analyzed by ELISA for noradrenaline (Labor Diagnostika Nord) and the urine was also analyzed for creatinine (Crystal Chem, Inc) to normalize the noradrenaline levels.